Welcome to our dedicated page for ZyVersa Therapeutics news (Ticker: $ZVSA), a resource for investors and traders seeking the latest updates and insights on ZyVersa Therapeutics stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect ZyVersa Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of ZyVersa Therapeutics's position in the market.
Rhea-AI Summary
ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA) announced a public offering of 4,000,000 shares of common stock and accompanying Series A and Series B warrants, resulting in gross proceeds of approximately $5.0 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-46.26%
Tags
-
Rhea-AI Summary
ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA) announces the publication of an article in the peer-reviewed journal, Diabetes, demonstrating that AIM2 and NLRP3 inflammasome activation contributes to the development of atherosclerosis in two different animal models of type 1 diabetes. Diabetic animals demonstrated activation of inflammasome pathways, and inhibiting these pathways with ZyVersa's Inflammasome ASC Inhibitor IC 100 showed reduced aortic lesion size in diabetic mice.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.38%
Tags
-
Rhea-AI Summary
ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA) has approved a 1-for-35 reverse stock split and an increase in authorized shares of capital stock. The reverse stock split will be effective on December 4, 2023, and the common stock is expected to begin trading on a reverse stock split-adjusted basis on Nasdaq on December 5, 2023. The reverse stock split is intended to increase the price per share of the Company’s common stock to allow the Company to demonstrate compliance with the $1.00 minimum bid price requirement for continued listing on Nasdaq, among other benefits.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-30.85%
Tags
Rhea-AI Summary
ZyVersa Therapeutics, Inc. (ZVSA) is progressing towards initiating a proof-of-concept clinical trial with Cholesterol Efflux Mediator™ VAR 200 in patients with diabetic kidney disease, with a planned Q1-2024 start date. They have also been granted a European patent for the use of VAR 200 in diabetic nephropathy/diabetic kidney disease. The company is nearing completion of pre-clinical requirements for GLP toxicology studies and subsequent IND submission. ZyVersa reported financial results for the third quarter of 2023, ending September 30, 2023, with net losses of approximately $2.9 million for the quarter.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.19%
Tags
-
Rhea-AI Summary
ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA) announces publication of a study demonstrating the effectiveness of NLRP3 inflammasome inhibition in treating inflammatory bowel disease (IBD). The study provides evidence that inhibiting NLRP3 signaling can significantly improve IBD symptoms and restore normal intestinal microbial flora. ZyVersa is developing Inflammasome ASC Inhibitor IC 100, designed to inhibit multiple types of inflammasomes and their associated ASC specks to control chronic inflammation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.13%
Tags
-
Rhea-AI Summary
ZyVersa Therapeutics, Inc. announces the publication of an article demonstrating that inhibiting NLRP3 inflammasomes can attenuate kidney damage caused by PM2.5 pollution. The research supports inflammasome inhibition as a potential treatment for kidney disease.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.27%
Tags
Rhea-AI Summary
ZyVersa Therapeutics, Inc. has published a study in Molecular Neurobiology demonstrating the neuroprotective effects of NLRP3 inflammasome inhibition in a mouse model of multiple sclerosis (MS). The study showed significant decreases in neuronal damage and demyelination with NLRP3 inhibition. MS affects around 2.1 million people worldwide and is characterized by neuron damage in the central nervous system, leading to physical and cognitive disability. ZyVersa is developing Inflammasome ASC Inhibitor IC 100, which aims to attenuate damaging inflammation by inhibiting the formation of inflammasomes and their associated ASC specks.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.76%
Tags
-
Rhea-AI Summary
Obesity exacerbates scarring of the heart's muscular tissue through inflammasome ASC recruitment to the heart's mitochondria, leading to damaging inflammation. ZyVersa Therapeutics announces a publication in Diabetes demonstrating the role of ASC in obesity-induced myocardial fibrosis. Inhibition of NLRP3 activation or removal of IL-1β and IL-18 abated adverse effects on cardiac fibrosis and function in mice.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.86%
Tags
-
Rhea-AI Summary
Chronic kidney disease worsens with age due to NLRP3 inflammasome signaling in the kidneys' filtration system, according to a study by ZyVersa Therapeutics.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.92%
Tags
Rhea-AI Summary
ZyVersa Therapeutics announces publication of a review paper highlighting the role of kidney cholesterol and lipid accumulation in chronic kidney disease (CKD) development and progression.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.4%
Tags
ZyVersa Therapeutics, Inc.
Nasdaq:ZVSA
ZVSA Rankings
ZVSA Stock Data
4.02M
7.50M
0.83%
2.65%
7.64%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
United States of America
SOMERVILLE
About ZVSA
variant pharmaceuticals is an orphan drug company leveraging advanced proprietary technologies to develop best-in-class drugs for patients with rare diseases. our accomplished leadership team, each with more than 15 years of demonstrated success in the biopharmaceutical and medical industries, focuses on assuring that our development efforts serve the needs of all our stakeholders: patients, health care providers, payors, and our investors. our evolving product pipeline is targeted to the $100+ billion orphan drug market. our lead orphan drug candidate is hydroxypropyl beta cyclodextrin (hpβcd) for chronic treatment of two orphan indications, var 200: focal segmental glomerulosclerosis (fsgs) and var 300: alport syndrome (as). both of these conditions are rare progressive forms of kidney disease associated with accumulation of cholesterol and lipids, contributing to impaired kidney function, ultimately leading to dialysis and/or kidney transplantation. hpβcd entraps and removes lipids